NUVB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	755 568
Średni wolumen	1.41M
Kapitalizacja rynkowa	702.11M
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $-0.100 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.20
ATR14	$0.00700 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Cui Xiangmin	Buy	4 183 002	Class A Common Stock
2024-04-09	Cui Xiangmin	Buy	1 675 236	Class A Common Stock
2024-04-09	Cui Xiangmin	Buy	314 106	Class A Common Stock
2024-04-09	Cui Xiangmin	Buy	0
2024-04-09	Sjogren Colleen	Buy	500 000	Stock Option (Right to Buy)

INSIDER POWER
94.07
Last 97 transactions
Buy: 43 735 081 \| Sell: 11 578 450

Wolumen Korelacja

Długi: 0.08 (neutral)

Krótki: 0.00 (neutral)

Signal:(43.128) Neutral

Panacea Acquisition Corp. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Panacea Acquisition Corp. Korelacja - Waluta/Towar

0.57
( weak )

0.31
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.31
( neutral )

Panacea Acquisition Corp. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-222 000 (0.00 %)
EPS:	$-0.350

FY	2023
Przychody:	$0
Zysk brutto:	$-222 000 (0.00 %)
EPS:	$-0.350

FY	2022
Przychody:	$0
Zysk brutto:	$-484 000 (0.00 %)
EPS:	$-0.410

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.440

Financial Reports:

No articles found.

Panacea Acquisition Corp.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.